sarcopenia and glp 1 GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenic Obesity | Current Nutrition Reports The Influence of Glucagon-like Peptide-1

sarcopenia and glp 1

sarcopenia and glp 1 GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenic Obesity | Current Nutrition Reports The Influence of Glucagon-like Peptide-1

Name: sarcopenia and glp 1 GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenic Obesity | Current Nutrition Reports The Influence of Glucagon-like Peptide-1
Brand: trading-ox.com
SKU: 30920728472
Price: 27.28 USD
Availability: InStock
Rating: 4.6831000000000005 (11 reviews)

SKU: 30920728472

4.7

USD27.28 USD57.28

Pay in 4 interest-free payments of $6.82 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 21 - Aug 26

Description

Silvestre, L.M

Acta Endocrinol 75:274, 1974

doi: 10.1016/j.drup.2022.100916 134 LaiYTangFHuangYHeCChenCZhaoJet al

Variation in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene that every GLP-1 compound targets), MC4R (a melanocortin receptor tied to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose handling and GLP-1 secretion) describes the metabolic terrain a compound acts on

Participants on semaglutide 2.4 mg lost a mean of 14.9% of baseline body weight over 68 weeks compared to 2.4% with placebo